ePRO, E-patient Diaries and eCOA Market By Component (Software, Services); By Delivery Mode (Cloud-Based, Web-Based, On-Premise); By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Medical Device Companies, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

ePRO, E-patient Diaries and eCOA Market: From Patient Voice to Digital Clinical Intelligence

The Global ePRO, E-patient Diaries and eCOA Market was valued at USD 2.38 Billion in 2025 and is projected to reach USD 6.18 Billion by 2032, growing at a CAGR of 14.6% during 2026–2032.

 

ePRO, e-patient diaries and eCOA are related but not identical clinical-trial technologies. ePRO captures outcomes reported directly by patients. E-patient diaries are a form of ePRO used for repeated or time-sensitive reporting such as daily symptoms, treatment effects and medication use. eCOA is the broader electronic framework that includes ePRO as well as clinician-reported, observer-reported and performance-based assessments.

 

Demand is increasing as clinical studies place greater emphasis on symptoms, physical function, treatment tolerability and quality of life. Electronic collection allows these outcomes to be recorded at home or during site visits while giving research teams more timely data than retrospective paper-based collection. FDA states that clinical outcome assessments can measure how patients feel or function, while patient-reported outcomes provide information directly from patients. FDA's October 2025 Patient-Focused Drug Development Guidance 3 further addresses the selection, development and modification of fit-for-purpose clinical outcome assessments for medical product development and regulatory decision-making.

 

The scale of clinical research creates a large base of studies in which electronic outcome collection can be applied. As of July 14, 2026, ClinicalTrials.gov listed 593,857 registered studies across 226 countries and territories, including 453,135 interventional studies and 65,004 actively recruiting studies. The registry also recorded 219,299 studies involving drugs or biologics and 62,833 involving devices, showing the breadth of clinical programs that may require patient, clinician or caregiver-reported outcome data.

The three areas should not be treated as separate additive markets. A daily electronic symptom diary can simultaneously be an e-patient diary, an ePRO instrument and part of an eCOA platform. The market figures therefore represent the combined technology and service environment without double-counting individual assessment formats.

 

Why Are ePRO and E-patient Diaries Gaining Greater Use in Clinical Trials?

ePRO Expands as Patient Experience Becomes a More Important Clinical Endpoint

ePRO is becoming increasingly important where treatment success cannot be assessed through laboratory or imaging results alone. Oncology, inflammatory diseases, neurology, respiratory disease and chronic conditions frequently require patients to report pain, fatigue, symptoms, physical limitations or treatment-related effects directly.

FDA's October 2025 Patient-Focused Drug Development Guidance 3 addresses the selection and development of fit-for-purpose clinical outcome assessments. FDA also recommends collection of patient-reported outcomes in areas such as cancer trials where symptoms and functional effects provide information that clinical measurements may not capture independently. FDA's final October 2024 guidance specifically recommends collection of a core set of patient-reported clinical outcomes in cancer trials and notes that related considerations may also apply to clinician-reported, observer-reported and performance outcomes.

Electronic reporting is particularly useful when responses are required between site visits. In oncology, ePRO systems can capture symptoms and adverse effects while treatment is underway. IQVIA noted in 2025 that real-time ePRO collection in oncology can also enable alert-based monitoring when patient responses indicate clinically relevant changes.

For example, Veeva's eCOA platform captures questionnaire responses directly from patients as ePRO through an application or webpage. Its validated instrument library includes more than 200 instruments, with numerous ePRO measures covering pain, quality of life, anxiety, gastrointestinal symptoms and other therapeutic endpoints.

 

E-patient Diaries Address Daily and Event-Based Symptom Reporting

E-patient diaries have a more specific role: they capture repeated information at predefined times or when an event occurs. Their importance increases when a trial endpoint depends on what happened during a particular day rather than what a patient remembers several weeks later.

This is especially relevant in inflammatory bowel disease. Daily diaries may record stool frequency, rectal bleeding, abdominal pain and general well-being. These measurements contribute directly to disease-activity assessments used in Crohn's disease and ulcerative colitis research.

Respiratory trials provide another clear example. A recent Signant case study involved 1,125 patients, 10 instruments and 55 languages. Participants used home-based electronic diaries during a global Phase III respiratory study, while study sites monitored completion during defined diary-entry periods.

The distinction matters commercially. ePRO demand grows with patient-centered endpoints, while e-patient diary demand is particularly strong in trials requiring daily, weekly or event-triggered symptom records. Both increase use of the software platforms and study services included in this market.

 

How Does Broader eCOA Expand Beyond Patient Diaries?

eCOA covers a wider set of electronic clinical assessments than ePRO alone. Along with patient-reported outcomes, an eCOA system can capture clinician-reported outcomes, caregiver or observer assessments and performance-based measures. Veeva's current eCOA framework, for example, captures responses from clinical-trial participants through ePRO, clinicians through eClinRO and caregivers through eObsRO.

This broader capability is important in therapeutic areas where treatment evaluation needs several perspectives. A patient may report pain or fatigue through ePRO. A clinician may complete a disease-severity scale. A caregiver may assess behavior or daily function. A performance assessment may measure whether the patient can complete a defined physical or cognitive task.

The market is therefore expanding from individual electronic questionnaires toward systems capable of handling several outcome types within the same study.

For example, Medidata states that its eCOA offering handles assessments ranging from simple electronic diaries to more complex clinician-reported assessments. The platform also connects patient assessments with other study interactions.

For example, Clario's eCOA activities span patient and site assessments, while its wider clinical endpoint portfolio includes imaging, cardiac, respiratory and digital physiology measurements. Its May 2025 acquisition of WCG's eCOA business added further assessment expertise, particularly in neuroscience.

This broader eCOA use increases the value of platforms that can manage multiple instruments, languages and assessment schedules without requiring separate systems for each outcome type.

 

Why Do Software and Cloud-Based Platforms Lead the Market?

Software — 62.0% Share and 15.7% CAGR

Software accounted for 62.0% of the market, or USD 1.48 Billion in 2025, and is projected to grow at 15.7% CAGR.

Its lead reflects demand across all three areas of the market. ePRO requires patient-facing questionnaires and applications. E-patient diaries require schedules, reminders and defined entry windows. Broader eCOA requires instrument management for patient, clinician, caregiver and performance assessments.

The continuing expansion of digital study activity increases the number of clinical programs requiring scalable electronic systems. ClinicalTrials.gov recorded 42,966 newly registered studies during 2025, compared with 23,307 in 2014, while total registered studies reached 593,857 by July 14, 2026.

For example, Medidata expanded its collaboration with CTI Clinical Trial and Consulting in November 2025 by adding its patient experience and eCOA capabilities to CTI's existing Rave environment. Medidata reported experience across more than 36,000 trials and 11 million patients.

 

Services — 38.0% Share and 12.8% CAGR

Services represented 38.0%, or USD 0.90 Billion in 2025, with a CAGR of 12.8%.

Translation, electronic migration, instrument configuration, usability work and study assistance remain necessary because an existing PRO questionnaire cannot simply be converted into a digital diary without considering its wording, timing and intended measurement properties.

C-Path's eCOA Consortium continues to publish work covering electronic implementation, data changes and patient-focused outcome collection, indicating that scientific implementation remains an important part of electronic assessment projects. In March 2025, C-Path announced the conclusion of its eCOA: Getting Better Together Initiative, a collaboration between its PRO and eCOA consortia focused on recurring electronic assessment implementation challenges.

 

Cloud-Based — 58.0% Share and 16.2% CAGR

Cloud-based solutions represented USD 1.38 Billion in 2025 and are the fastest-growing delivery mode at 16.2% CAGR.

Cloud access is well suited to studies where patients complete ePRO or diary entries from home while clinicians and research teams review assessments from different locations. It also facilitates connections between eCOA and other trial applications.

The geographic distribution of current trials reinforces the need for systems that operate beyond individual research locations. Of the 65,004 recruiting studies listed by ClinicalTrials.gov on July 14, 2026, 42,836, or 66%, were non-U.S.-only studies, while another 3,096, or 5%, included both U.S. and non-U.S. locations.

Veeva's 2025 collaboration with Amgen covers a clinical platform containing eCOA, EDC, CTMS, RTSM, eTMF and other applications, illustrating the movement toward connected trial technology.

Web-based solutions accounted for 30.0%, or USD 0.71 Billion, with a CAGR of 12.9%. They remain relevant for browser-based patient and site assessments.

On-premise solutions represented 12.0%, or USD 0.29 Billion, with an 8.6% CAGR. Their slower growth reflects stronger adoption of hosted systems for geographically distributed trials.

 

Which Organizations Use ePRO, E-patient Diaries and eCOA Most?

Pharmaceutical and Biotechnology Companies — 46.0%

Pharmaceutical and biotechnology companies accounted for USD 1.09 Billion in 2025 and are the largest end-user segment with a 46.0% share. Their CAGR is 15.3%.

Drug developers use ePRO to measure symptoms and quality of life. They use e-patient diaries when repeated symptom records are required. They use broader eCOA when trials also need clinician, caregiver or performance assessments.

The underlying drug-development activity is substantial. ClinicalTrials.gov recorded 219,299 registered studies involving a drug or biologic as of July 14, 2026, with 52,699 of these studies having posted results. A study can involve more than one intervention type, so these categories are not mutually exclusive.

Increasing attention to patient-focused endpoints is especially relevant for this group. FDA's current regulatory-science work emphasizes outcomes that reflect how patients feel and function. FDA's Oncology Center of Excellence also states that its Patient-Focused Drug Development program uses rigorous methods to assess patient experience alongside survival and tumor information.

 

Contract Research Organizations — 27.0%

CROs held 27.0%, equal to USD 0.64 Billion, with a 14.8% CAGR.

CROs need technologies that can be applied across several therapeutic areas and multinational studies. CTI's 2025 expansion with Medidata is one example of a CRO adding eCOA capabilities within its broader clinical-data operations.

 

Medical Device Companies — 15.0%

Medical device companies accounted for USD 0.36 Billion and have a CAGR of 13.2%.

Electronic patient reports are relevant when device studies evaluate pain, mobility, physical functioning or treatment experience. Broader eCOA can also capture clinician assessments used alongside device-performance measurements. FDA recognizes COAs and PRO instruments within medical-device evaluation.

ClinicalTrials.gov recorded 62,833 registered studies involving devices as of July 14, 2026, of which 11,334 had posted results. The registry also notes that intervention categories can overlap when a study evaluates more than one intervention type.

 

Academic and Research Institutes — 12.0%

Academic and research institutes represented USD 0.29 Billion and grow at 11.6%.

Their use is concentrated in clinical research, instrument validation and studies examining how patient-reported information can improve measurement of treatment outcomes.

 

Which Regions Are Expanding ePRO, E-patient Diary and eCOA Use?

North America — 39.0%

North America led with USD 0.93 Billion in 2025 and a 13.8% CAGR.

The region benefits from a large pharmaceutical and biotechnology research sector and continued FDA emphasis on patient-focused outcome measurement. U.S.-based oncology research is particularly relevant for ePRO because patient symptoms and treatment effects are increasingly collected alongside conventional clinical endpoints.

ClinicalTrials.gov data show the continuing scale of U.S. research activity. As of July 14, 2026, 167,622 registered studies, or 28% of the global registry, were U.S.-only, while another 25,887 studies, or 4%, included both U.S. and international locations. Among recruiting studies, 19,072 were U.S.-only and 3,096 included both U.S. and non-U.S. locations.

 

Europe — 29.0%

Europe accounted for USD 0.69 Billion and is expected to grow at 14.1%.

By the end of 2025, the EU Clinical Trials Information System had received 13,110 initial trial applications, while more than 6,110 trials were ongoing under the Clinical Trials Regulation. Multinational European studies increase the need for electronic instruments that can be translated and deployed consistently across countries.

The multinational structure is particularly relevant for ePRO and eCOA deployment. As of December 31, 2025, 4,847 multinational clinical trials had a decision in CTIS, with an average of six EU/EEA Member States concerned per trial. CTIS reported 6,116 ongoing trials in which recruitment had started in at least one participating Member State.

 

Asia-Pacific — 22.0%

Asia-Pacific represented USD 0.52 Billion and has the fastest regional CAGR at 16.9%.

Its growth reflects expansion in clinical research activity and greater participation in multinational trials. The resulting studies require electronic patient questionnaires and diaries that can work across languages and locations.

WHO data show the scale of this shift. The organization reported 31,097 registered trials in the Western Pacific in 2025, more than 30 times the 822 recorded in Africa. WHO also identifies China and Japan as the largest contributors within the Western Pacific and reports that South-East Asia has continued to expand, with India accounting for approximately 85% of trials in the region and almost 10% of trials globally.

 

Latin America — 6.0%

Latin America accounted for USD 0.14 Billion with a 12.5% CAGR. Growth is linked to greater participation in multinational studies, where consistent ePRO and e-patient diary collection helps maintain common outcome measures across countries.

Clinical-research infrastructure is also receiving greater regional policy attention. In April 2026, the Pan American Health Organization launched its Clinical Trial Accelerator, an initiative designed to improve the quality, scale and impact of clinical research across the Americas.

 

Middle East & Africa — 4.0%

Middle East & Africa represented USD 0.10 Billion and is projected to grow at 11.8%. Adoption remains more concentrated in established research centers and multinational programs.

WHO recorded 822 registered trials in Africa in 2025, compared with 31,097 in the Western Pacific. The difference helps explain why electronic clinical outcome technology adoption remains smaller in Africa while offering room for longer-term expansion as clinical research activity broadens.

 

Competition Expands Across ePRO, Electronic Diaries and Broader eCOA

Competition is no longer limited to providing electronic questionnaires. Companies are differentiating through patient applications, diary functionality, instrument libraries, clinician assessments and connections with other clinical technologies.

Medidata

Medidata provides ePRO, electronic diaries and wider eCOA capabilities through its patient experience environment. Its eCOA offering ranges from simple eDiaries to more complex clinician assessments. Medidata reported experience across more than 36,000 trials and 11 million patients.

 

Signant Health

Signant provides ePRO, electronic patient diaries and other eCOA assessment types. A global respiratory study using its technology involved 1,125 patients and 55 languages, providing direct evidence of large-scale electronic diary deployment. In May 2026, Signant also completed its acquisition of Ametris to combine eCOA with sensor-generated measurements.

 

Veeva Systems

Veeva eCOA captures ePRO, eClinRO and eObsRO responses. Its library includes more than 200 validated instruments, and the company's wider clinical platform connects eCOA with EDC, RTSM and other applications.

 

Clario

Clario provides ePRO and broader electronic outcome assessments alongside specialized clinical endpoints. Its acquisition of WCG's eCOA business in May 2025 expanded its presence in assessment-intensive therapeutic areas such as neuroscience.

 

IQVIA

IQVIA combines electronic patient-reported outcomes with wider eCOA technology. Its current offering includes more than 2,500 pre-validated digital instruments, while its therapeutic work covers areas including oncology, rheumatoid arthritis, obesity and respiratory studies. The company reports average patient protocol compliance above 90% across its Patient Suite; this remains a company-reported metric.

 

What Could Limit Market Growth?

Patient burden and study-design complexity remain major limitations across ePRO, e-patient diaries and eCOA.

For ePRO, questionnaires must measure concepts that are meaningful to patients. For e-patient diaries, frequency and completion windows must be designed so participants can report events without excessive burden. For broader eCOA, research teams must manage multiple assessment types, languages and data flows.

Poor diary design can reduce completion and create missing information. Signant's current guidance specifically identifies frequency, recall period and completion windows as important elements of electronic patient diary design.

Regulatory attention also increases the need for well-designed outcome measures rather than electronic collection alone. FDA's October 2025 Guidance 3 states that fit-for-purpose COAs should be selected, developed or modified so that patient-experience information can contribute appropriately to medical-product development and regulatory decision-making. FDA's oncology guidance separately recommends systematic collection of core patient-reported outcomes in cancer clinical trials.

The strongest market expansion is therefore likely to come from systems that make ePRO easier for patients, electronic diaries easier to complete at the required time, and broader eCOA easier to manage across multiple assessment types. This balanced demand across the three areas supports the supplied market forecast of USD 6.18 Billion by 2032.

 

ePRO, E-patient Diaries and eCOA Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.38 Billion
Revenue Forecast in 2032	USD 6.18 Billion
Overall Growth Rate	CAGR of 14.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Component, By Delivery Mode, By End User, By Geography
By Component	Software, Services
By Delivery Mode	Cloud-Based, Web-Based, On-Premise
By End User	Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Medical Device Companies, Academic and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising use of patient-reported outcomes in clinical trials, increasing adoption of electronic patient diaries, expansion of decentralized and multinational studies, growing use of cloud-based eCOA platforms, and greater focus on patient-centered clinical endpoints
Customization Option	Available upon request